Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics - Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ; Schjesvold, Fredrik (University of Oslo) ; Weisel, Katja (University Medical Center Hamburg-Eppendorf) ; Moreau, Philippe (University Hospital Hôtel-Dieu) ; Anderson, Larry D. (University of Texas Southwestern Medical Center) ; White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Sonneveld, Pieter (Erasmus MC Cancer Institute) ; Engelhardt, Monika (Universitätsklinikum Freiburg) ; Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Corso, Alessandro (Hospital of Legnano) ; Dürig, Jan (University Hospital Essen (Alemanya)) ; Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ; Salomo, Morten (Copenhagen University Hospital) ; Beksac, Meral (Ankara University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ; Liberati, Anna Marina (University of Perugia) ; Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ; Robak, Pawel (Medical University of Lodz) ; Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ; Yagci, Munci (Gazi University Medical Faculty) ; Vural, Filiz (Ege University) ; Kanate, Abraham (West Virginia University) ; Jiang, Ruiyun (Bristol Myers Squibb) ; Grote, Lara (Bristol Myers Squibb) ; Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ; Dimopoulos, Meletios (National and Kapodistrian University of Athens)